Dr. Reddy's Laboratories can look ahead to providing “the complete standard of care for HER2-positive breast cancer patients in India,” after striking a deal for Zydus Lifesciences’s biosimilar to Genentech’s Perjeta (pertuzumab).
Reddy’s, Zydus Shake Hands On Next-Generation Pertuzumab In India
Reddy’s Already Offers Trastuzumab, Which Is Used With Pertuzumab
Two major Indian players have formed an alliance to bring a biosimilar to Genentech’s Perjeta to their local market, having already debuted several treatments in the HER2-positive breast cancer space.
More from Deals
More from Business
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
• By
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.